ProShare Advisors
LEGN icon

ProShare Advisors’s Legend Biotech LEGN Stock Holding History

ProShare Advisors’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,827
Closed -$235K – 2283
2024
Q3 		$235K Sell
4,827
-216
-4% -$11.5K ﹤0.01% 1636
2024
Q2 		$223K Sell
5,043
-542
-10% -$25K ﹤0.01% 1477
2024
Q1 		$313K Buy
5,585
+494
+10% +$29.8K ﹤0.01% 1406
2023
Q4 		$306K Sell
5,091
-118
-2% -$7.48K ﹤0.01% 1355
2023
Q3 		$350K Buy
5,209
+1,016
+24% +$70.6K ﹤0.01% 1123
2023
Q2 		$289K Sell
4,193
-299
-7% -$19.5K ﹤0.01% 1298
2023
Q1 		$217K Sell
4,492
-866
-16% -$42.4K ﹤0.01% 1406
2022
Q4 		$267K Buy
+5,358
New +$260K ﹤0.01% 1307
2022
Q3 		– Sell
-4,149
Closed -$228K – 1783
2022
Q2 		$228K Sell
4,149
-1,416
-25% -$59.8K ﹤0.01% 1390
2022
Q1 		$202K Sell
5,565
-702
-11% -$27.7K ﹤0.01% 1882
2021
Q4 		$292K Sell
6,267
-559
-8% -$28.4K ﹤0.01% 1805
2021
Q3 		$345K Buy
+6,826
New +$284K ﹤0.01% 1446

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

ProShare Advisors's LEGN Position: Q4 2024 in Review

ProShare Advisors sold out of Legend Biotech (LEGN) in Q4 2024, closing a stake of 4,827 shares — an estimated $235K sold.

ProShare Advisors first reported a position in LEGN in Q3 2021 and held it in 12 quarters. The position peaked at $350K in Q3 2023. 211 funds tracked by Wall St. Rank hold LEGN as of Q4 2024.

  • ProShare Advisors reported no remaining Legend Biotech position as of Q4 2024 after selling out during the quarter.
  • ProShare Advisors sold 4,827 Legend Biotech shares in Q4 2024, an estimated $235K.
  • ProShare Advisors first reported a position in Legend Biotech in Q3 2021 and held it in 12 quarters.
  • ProShare Advisors's Legend Biotech position peaked at $350K in Q3 2023.
  • 211 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2024.

Based on ProShare Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.